THERAPEUTIC AREA PRODUCT STATUS PARTNER
MARKETED PORTFOLIO HBV, HCV, Cancer, Immune System Enhancer; Sepsis ZADAXIN Marketed since 1996 SciClone Proprietary

Oncology

Holoxan

Mesna

Endoxan

Methotrexate

Farlutal

Estracyt

DC Bead

Marketed

Marketed

Marketed

Marketed

Marketed

Marketed

Marketed

Baxter

Baxter

Baxter

Pfizer

Pfizer

Pfizer

BTG


ZADAXIN®

ZADAXIN® (thymalfasin) is a synthetic version of thymosin alpha 1, a substance found naturally in the circulation and produced in the body’s thymus gland. ZADAXIN stimulates the immune system to better fight infectious diseases and cancers. It is this ability to act as an immune system enhancer that makes it a promising therapy for such a wide variety of clinical conditions. ZADAXIN is approved in over 30 countries worldwide for several different clinical indications, and may be used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and certain cancers, and as an immune system enhancer, according to the approvals we have in these countries.

Introduced to the China market in 1996, ZADAXIN continues to be a major growth driver for our company. Today, utilization of the product is mainly in oncology indications and chronic hepatitis, and demand in these markets remains strong. We continue to anticipate growth opportunities for ZADAXIN in the indications for which it is currently approved as well as in potential new indications. We believe that the therapeutic areas of hepatitis B and sepsis continue to represent growth areas for ZADAXIN, and are continuing to implement academic marketing strategies to deepen market penetration.

In the HBV market, which represents a very large commercial opportunity for ZADAXIN, we are deploying a medical education-focused strategy. This includes mobilizing our MSLs to directly interface with physicians to discuss the data supporting the use of the drug in HBV, and highlight the benefits of our product within the thymalfasin class. We are also hosting symposia with physicians, for which they can get CME credit, in a medical education environment which focuses on the data supporting the use of ZADAXIN in HBV. Additionally, we are cultivating the support of key opinion leaders in HBV, and creating an extensive ZADAXIN utilization database in China, including data in different HBV patient populations, that we believe will be highly informative about the product’s therapeutic benefits.

In the area of sepsis, we are undertaking similar medical education initiatives, carried out by our MSLs and directed to physicians and key opinion leaders. In these discussions, our MSLs are citing the encouraging results from the completed sepsis trial in China, and informing physicians of the large Phase 3 trial in sepsis being implemented by China researchers, for which results should be available in about two years.

To build utilization further, we are working to open more channels to directly support physician prescribing outside of the typical hospital channel. We are utilizing tools and techniques to reach directly to patients after they leave the hospital setting, and can exercise more choice in their prescriptions.

For example, we are working with key players in our supply chain – most notably SinoPharm, our exclusive ZADAXIN importer – to leverage their channels that directly reach patients through their retail pharmacy network. In this way, we are keeping pace with a key market structural change, as patients increasingly purchase their prescriptions from retail pharmacies, rather than hospital pharmacies.

Market indicators suggest that traditional Chinese medicine is likely to remain a major market category for at least the next decade, underscoring ZADAXIN’s value as a proven product with a differentiated Western pedigree. In a highly competitive marketplace in which the generic companies have no differentiation based on quality, but can only compete on price, we are very pleased with the continued strength of ZADAXIN sales and maintenance of its leading market position. We believe that we can continue to achieve our goal of growing ZADAXIN in line with China pharma market growth, and potentially exceed that growth rate over the next several years.


DC Bead

DC BEAD®

DC Bead® is an embolic bead delivered through a minimally invasive, non-surgical procedure to block the blood flow to tumors. DC Bead was registered in China in August 2014 for the embolization of malignant hypervascularized tumors such as hepatocellular carcinoma, or HCC. HCC is the most common form of primary liver cancer, and more than 350,000 people die from primary liver cancer in China annually. We have an exclusive licensing and distribution agreement with BTG plc for the China market.  

Our market introduction and launch activities, initiated in the second quarter of 2015, have been focused on medical education in the major centers where interventional cancer treatment is performed, as well as on carefully training intervention oncologists in the use of the product. Our expert team of MSLs is critical to this educational strategy, as intensive physician-to-physician training on the proper placement of the beads within the blood vessel is critical. We intend to continue this intensive medical education strategy, including utilizing the support of physicians and KOLs from other countries, such as the US and Japan, where the use of DC Bead is established.

We have a team of about 20 professionals focused on the DC Bead launch. This investment in medical education is an important step to maximizing the product’s commercial potential, as we believe that DC Bead represents a superior therapeutic alternative in a very large market segment.   


OTHER MARKETED PRODUCTS

We have established promotion services agreements with leading pharmaceutical companies to promote their products in the China market.

We promote the following products for Baxter:

  • Holoxan™: an oncology product indicated for bone and soft tumors, lymphoma, lung cancer, cervical cancer, ovarian cancer, testimular cancer and child solid tumors, bladder cancer, head and neck cancer and breast cancer
  • Mesna™: to treat urotoxicity (combined with ifosfamide)
  • Endoxan™: an oncology product to treat breast cancer, ovarian cancer, small cell lung cancer and sarcoma

We promote the following products for Pfizer:

  • Farlutal™: an oncology product to treat breast cancer, carcinoma of the endometrium, prostate cancer and renal cancer
  • Methotrexate™: an oncology product to treat acute leukemia, osteosarcoma and breast cancer
  • Estracyt™: an oncology product to treat hormone-resistant advanced prostate cancer
© 2017 SciClone Pharmaceuticals, Inc. All rights reserved. Please read our disclaimer. Terms of Use | Notes Regarding Forward Looking Statements